Sign In
Buy ACAD
$22.60
+0.510 (+2.31%)
At Close: Jun 23, 2026
Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome
04:07pm, Wednesday, 16'th Oct 2024
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Health Canada has granted marketing authorization of DAYBUE™ (trofinetide) for the treatment of Rett syndr
Why Acadia (ACAD) Could Beat Earnings Estimates Again
01:11pm, Monday, 14'th Oct 2024
Acadia (ACAD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
ACAD or TECH: Which Is the Better Value Stock Right Now?
12:48pm, Wednesday, 09'th Oct 2024
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Acadia Pharmaceuticals (ACAD) and Techne (TECH). But which of these two stocks is more attractive to
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Tuesday, 08'th Oct 2024
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on October 3, 2024, the Compensation Committee of Acadia's Board of Directors (the “Committee”) granted
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Thursday, 26'th Sep 2024
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on September 23, 2024, the Board of Directors granted Catherine Owen Adams, Acadia's new Chief Executive Off
Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals
04:15pm, Monday, 23'rd Sep 2024
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Catherine Owen Adams has succeeded Steve Davis as Chief Executive Officer (CEO) and joined the Acadia Board
Axcelead Drug Discovery Partners Enters into Master Service Agreement for Drug Discovery Projects with Acadia Pharmaceuticals
12:00pm, Thursday, 19'th Sep 2024
TOKYO--(BUSINESS WIRE)-- #DrugDiscovery--Axcelead Drug Discovery Partners Enters into Master Service Agreement for Drug Discovery Projects with Acadia Pharmaceuticals.
Acadia (ACAD) Up 10% Since Last Earnings Report: Can It Continue?
12:37pm, Thursday, 05'th Sep 2024
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
04:05pm, Wednesday, 28'th Aug 2024
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor conferences: Morgan Stanley 22nd Annual Global Healthcare Confe
Acadia Pharmaceuticals: Nuplazid Performs In Q2 While Daybue Disappoints Again
03:02pm, Monday, 26'th Aug 2024
Shares of Acadia trended lower this year due to Daybue's poor quarterly sales performance, and also due to Nuplazid's failure in the phase 3 trial in schizophrenia patients. The full-year guidance on
Ryan Reynolds Announces More to Parkinson's® Campaign
08:04am, Wednesday, 14'th Aug 2024
SAN DIEGO--(BUSINESS WIRE)--Ryan Reynolds, a world-renowned actor/entrepreneur and Parkinson's disease advocate, with Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the launch of a multi-f
Acadia (ACAD) Q2 Earnings Beat, Product Sales Drive Revenues
09:21am, Wednesday, 07'th Aug 2024
Acadia (ACAD) reports encouraging second-quarter results as both earnings and revenues beat estimates, driven by higher Nuplazid and Daybue sales.
ACADIA Pharmaceuticals Inc. (ACAD) Q2 2024 Earnings Call Transcript
10:15pm, Tuesday, 06'th Aug 2024
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Al Kildani - Senior Vice President, Investor Relations and Corporate Communic
Acadia Pharmaceuticals (ACAD) Beats Q2 Earnings and Revenue Estimates
06:47pm, Tuesday, 06'th Aug 2024
Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.20 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.01 per share a year ago.
Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
11:07am, Tuesday, 30'th Jul 2024
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
